|
業務類別
|
Biotechnology |
|
業務概覽
|
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies. |
| 公司地址
| 11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 979 446-0027 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ibioinc.com |
| 員工數量
| 23 |
| Dr. Martin B. Brenner, PhD |
Director, Chief Executive Officer and Chief Scientific Officer |
美元 580.00K |
04/09/2026 |
| Mr. Felipe Duran |
Chief Financial Officer and Principal Accounting Officer |
美元 415.50K |
04/09/2026 |
| Mr. Marc Banjak |
Chief Legal Officer |
美元 400.00K |
04/09/2026 |
| Ms. Molly Carr, M.D. |
Chief Medical Officer |
-- |
04/08/2026 |
| Dr. Molly Carr |
Chief Medical Officer |
-- |
04/09/2026 |
|
|
| Mr. William D. Clark |
Chairman of the Board |
04/09/2026 |
| Dr. Elizabeth Stoner,M.D. |
Independent Director |
04/09/2026 |
| Mr. David A. Arkowitz, M.B.A. |
Independent Director |
04/09/2026 |
| Mr. Gary L. Sender |
Independent Director |
04/09/2026 |
| Dr. Martin B. Brenner, PhD |
Director, Chief Executive Officer and Chief Scientific Officer |
04/09/2026 |
| Dr. Alexandra Kropotova, M.D. |
Independent Director |
04/09/2026 |
| Mr. Antonio Bernardino Guimaraes Parada |
Independent Director |
04/09/2026 |
|
|
|
|
